SAFE-LCD: Can the combination of continuous glucose monitoring and a digital low calorie diet programme make Type 2 diabetes remission achievable and safe in people on insulin therapy?

SAFE-LCD：连续血糖监测和数字化低热量饮食计划相结合能否使接受胰岛素治疗的患者安全且安全地缓解 2 型糖尿病？

• 批准号: 10036336
• 金额: $ 60.73万
• 依托单位: OVIVA UK LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10036336
• 关键词: SAFE; LCD; combination; continuous; glucose

Type 2 diabetes (T2D) affects 4.1 million people in the UK, with many requiring medication to help control their blood sugars, and those with advanced T2D requiring daily insulin injections. Insulin treatment is linked to poorer quality of life and increased risk of complications due to disease progression.Longer-term, T2D is associated with a range of devastating complications including blindness, kidney failure, lower limb amputation and stroke. Recent research shows this is largely preventable with weight loss for the 90% of people with T2D who are overweight/obese.COVID has exacerbated pre-existing health inequalities driven by T2D, and new treatments are needed.The DiRECT clinical trial showed substantial weight loss (of 10-15kg) using a low-calorie diet (approx. 800kcal/day) for 12-weeks helps people reduce or even stop their diabetes medications, with nearly half able to put their T2D into remission (defined as normal blood sugar levels and stopped all diabetes medications).New research from University College London (UCL) used the same low-calorie diet for people on insulin and found that 39% of participants could stop insulin completely and overall insulin doses reduced by 75%. Despite this finding, people treated with insulin don't have access to low-calorie diets in the NHS today, with NHS commissioners stating they need more evidence such programmes can be delivered safely at a price they can afford.The challenge with the UCL and DiRECT studies was they used expensive in-person support, which is also hard for people to access, requiring time off work or care commitments and often high travel costs. Hard-to-attend appointments can make people less likely to stay on the diet and achieve a good outcome.Oviva's 100% remote, digital Diabetes Remission low-calorie diet programme for adults with T2D has shown superior access, outcomes and cost-effectiveness for NHS patients than in-person models, but this does not yet support insulin-treated patients.This project aims to develop and test a new low-calorie diet programme for adults with T2D who are insulin-treated (called Oviva Diabetes Remission-Insulin). Oviva will work with UCL to design the programme and then evaluate it in a research study with NHS Hull University Teaching Hospitals.The programme includes:* Specialist dietitian support throughout.* The Oviva app for participants to track their food, weight and health, and access a 12-month weight prediction chart to keep them on track.* The latest sugar and weight monitoring technology to ensure participants are safely supported as they come off their insulin.

2型糖尿病（T2D）在英国影响410万人，许多人需要药物来帮助控制其血糖，而患有晚期T2D的患者需要每日注射胰岛素。胰岛素治疗与较差的生活质量和由于疾病进展引起的并发症的风险增加有关。长期，T2D与一系列毁灭性并发症有关，包括失明，肾衰竭，下肢截肢和中风。最近的研究表明，这在很大程度上是可以预防的，对于90％的超重/肥胖者的T2D患者的体重减轻。COVID加剧了由T2D驱动的预先存在的健康不平等现象，需要新的治疗方法，并且需要新的临床试验。显示了使用低水平饮食的大量体重（即10-15kg），甚至是大约800年的for.800kcal for.800kcc ccc ccc cc ccc cccc ccc ccc cc ccc ccc ccc ccc ccc ccc cc cc cc cc cc cc cc cc cc coc cod ofe of。糖尿病药物，几乎一半能够使其T2D缓解（定义为正常血糖水平并阻止所有糖尿病药物）。伦敦大学学院（UCL）的新研究使用了胰岛素患者的相同低热量饮食，并发现39％的参与者可以完全降低胰岛素剂量，并将胰岛素完全降低75％。尽管有这一发现，但接受胰岛素治疗的人今天无法获得NHS的低热量饮食，NHS专员说，他们需要更多的证据可以以他们所能负担的价格安全地交付这些计划。对UCL和直接研究的挑战是他们使用了昂贵的个人支持，这也很难访问人们，需要花费时间或照顾时间或高级旅行费用和高级旅行成本。 Hard-to-attend appointments can make people less likely to stay on the diet and achieve a good outcome.Oviva's 100% remote, digital Diabetes Remission low-calorie diet programme for adults with T2D has shown superior access, outcomes and cost-effectiveness for NHS patients than in-person models, but this does not yet support insulin-treated patients.This project aims to develop and test a new low-calorie diet programme for adults with T2D胰岛素治疗的人（称为Oviva糖尿病缓解胰岛素）。 Oviva将与UCL合作设计该计划，然后在NHS Hull University教学医院的一项研究中对其进行评估。该计划包括：*专家营养师支持。